Ansan, South Korea
Ansan, South Korea

Time filter

Source Type

Kang S.-W.,Korea Conformity Laboratories | Shim S.-B.,Shin Poong Pharmaceutical Co. | Yoo J.,Korea University | Jung J.,Korea University
Bulletin of Environmental Contamination and Toxicology | Year: 2012

Gamma-ray treatment of phenol was studied in terms of both chemical degradation and toxicological change. About 90 % of phenol (5.0 × 10 -4 M) in ultra-pure water (UW) was eliminated by gamma-irradiation at a dose of 10 kGy, but acute toxicity was dramatically increased, particularly for dose of 1 kGy, due to the formation of more toxic by-products such as hydroquinone, benzoquinone, resorcinol and catechol. The addition of TiO2 nanoparticles had little effect on the removal of phenol in UW, but substantially enhanced the mineralization of phenol compared with gamma-irradiation alone. Additionally, degradation of phenol by gamma-irradiation was inhibited in a wastewater effluent (WE) matrix, likely due to the presence of dissolved organic carbon (22.06 mg L-1). Furthermore, lower concentrations of toxic by-products were generated both in WE and in the presence of TiO2 nanoparticles, resulting in reduction of toxicity increase by gamma-irradiation. Meanwhile, the toxicity of gamma-ray treated phenol in WE was well estimated with simple summation of individual toxicity of phenol and by-products (R2 = 0.9678). © Springer Science+Business Media, LLC 2012.


Rueangweerayut R.,Mae Sot General Hospital | Phyo A.P.,Shoklo Malaria Research Unit | Uthaisin C.,Mae Ramat Hospital | Poravuth Y.,National Malaria Center | And 9 more authors.
New England Journal of Medicine | Year: 2012

BACKGROUND: Pyronaridine-artesunate is an artemisinin-based combination therapy under evaluation for the treatment of Plasmodium falciparum and P. vivax malaria. METHODS: We conducted a phase 3, open-label, multicenter, noninferiority trial that included 1271 patients between 3 and 60 years of age from Asia (81.3%) or Africa (18.7%) with microscopically confirmed, uncomplicated P. falciparum malaria. Patients underwent randomization for treatment with a fixed-dose combination of 180 mg of pyronaridine and 60 mg of artesunate or with 250 mg of mefloquine plus 100 mg of artesunate. Doses were calculated according to body weight and administered once daily for 3 days. RESULTS: Pyronaridine-artesunate was noninferior to mefloquine plus artesunate for the primary outcome: adequate clinical and parasitologic response in the per-protocol population on day 28, corrected for reinfection with the use of polymerase-chain-reaction (PCR) genotyping. For this outcome, efficacy in the group receiving pyronaridine-artesunate was 99.2% (743 of 749 patients; 95% confidence interval [CI], 98.3 to 99.7) and that in the group receiving mefloquine plus artesunate was 97.8% (360 of 368 patients; 95% CI, 95.8 to 99.1), with a treatment difference of 1.4 percentage points (95% CI, 0.0 to 3.5; P = 0.05). In the intention-to-treat population, efficacy on day 42 in the group receiving pyronaridine-artesunate was 83.1% (705 of 848 patients; 95% CI, 80.4 to 85.6) and that in the group receiving mefloquine plus artesunate was 83.9% (355 of 423 patients; 95% CI, 80.1 to 87.3). In Cambodia, where there were 211 study patients, the median parasite clearance time was prolonged for both treatments: 64 hours versus 16.0 to 38.9 hours in other countries (P<0.001, on the basis of Kaplan-Meier estimates). Kaplan-Meier estimates of the recrudescence rate in the intention-to-treat population in Cambodia until day 42 were higher with pyronaridine-artesunate than with mefloquine plus artesunate (10.2% [95% CI, 5.4 to 18.6] vs. 0%; P = 0.04 as calculated with the log-rank test), but similar for the other countries combined (4.7% [95% CI, 3.3 to 6.7] and 2.8% [95% CI, 1.5 to 5.3], respectively; P = 0.24). Elevated levels of aminotransferases were observed in those receiving pyronaridine-artesunate. Two patients receiving mefloquine plus artesunate had seizures. CONCLUSIONS: Fixed-dose pyronaridine-artesunate was efficacious in the treatment of uncomplicated P. falciparum malaria. In Cambodia, extended parasite clearance times were suggestive of in vivo resistance to artemisinin. (Funded by Shin Poong Pharmaceutical Company and the Medicines for Malaria Venture; ClinicalTrials.gov number, NCT00403260.) Copyright © 2012 Massachusetts Medical Society.


Patent
Shin Poong Pharmaceutical Co. and Postech Academy Industry Foundation | Date: 2011-10-05

The present invention relates to a composition for preventing tissue adhesion which comprising a bio-compatible hyaluronic acid and a polymer compound. More specifically, the invention is a composition containing hyaluronic acid which has not been modified by a chemical crosslinking or other chemical modification a method for preparing the same, and a composition for adhesion prevention with superior efficacy.. The composition of the present invention for preventing adhesion exhibits a physical barrier function and a new adhesion prevention function whereby thrombus formation, which is the basis of adhesion, is inhibited. Unlike conventional compositions which simply mixpolymeric substances that function as physical barriers, the present invention performs a more effective role as a physical barrier by undergoing decomposition, absorption and excretion after a certain period inside a human body, does not interfere with healing of scars following surgery, and exhibits superior effects since application to areas of surgery is convenient.


Duparc S.,International Center Cointrin | Borghini-Fuhrer I.,International Center Cointrin | Craft C.J.,International Center Cointrin | Arbe-Barnes S.,Aptiv Solutions | And 3 more authors.
Malaria Journal | Year: 2013

Background: Pyronaridine-artesunate (PA) is indicated for the treatment of acute uncomplicated Plasmodium falciparum and Plasmodium vivax malaria. Methods. Individual patient data on safety outcomes were integrated from six randomized clinical trials conducted in Africa and Asia in patients with microscopically confirmed P. falciparum (five studies) or P. vivax (one study) malaria. Efficacy against P. falciparum was evaluated across three Phase III clinical trials. Results: The safety population included 2,815 patients randomized to PA, 1,254 to comparators: mefloquine + artesunate (MQ + AS), artemether-lumefantrine (AL), or chloroquine. All treatments were generally well tolerated. Adverse events occurred in 57.2% (1,611/2,815) of patients with PA versus 51.5% (646/1,254) for comparators, most commonly (PA; comparators): headache (10.6%; 9.9%), cough (5.9%; 5.6%) and anaemia (4.5%; 2.9%). Serious averse events were uncommon for all treatments (0-0.7%). Transient increases in alanine aminotransferase and aspartate aminotransferase were observed with PA but did not lead to any clinical sequelae. For P. falciparum malaria, day-28 PCR-corrected adequate clinical and parasitological response with PA was 93.6% ([1,921/2,052] 95% CI 92.6, 94.7) in the intent-to-treat population and 98.5% ([1,852/1,880] 95% CI 98.0, 99.1) in the per-protocol population. Median parasite clearance time was 24.1 h with PA, 31.9 h with MQ + AS, and 24.0 h with AL. Median fever clearance time was 15.5 h with PA, 15.8 h with MQ + AS, and 14.0 h with AL. By day 42, P. falciparum gametocytes had declined to near zero for all treatments. Conclusions: Pyronaridine-artesunate was well tolerated with no safety concerns with the exception of mostly mild transient rises in transaminases. Efficacy was high and met the requirements for use as first-line therapy. Pyronaridine-artesunate should be considered for inclusion in malaria treatment programmes. Trial registration. Clinicaltrials.gov: NCT00331136; NCT00403260; NCT00422084; NCT00440999; NCT00541385; NCT01594931. © 2013 Duparc et al; licensee BioMed Central Ltd.


Ali M.,Yonsei University | Hwang E.,Shinpoong Pharmaceutical Co. | Cho I.-H.,Shinpoong Pharmaceutical Co. | Moon M.H.,Yonsei University
Analytical and Bioanalytical Chemistry | Year: 2012

We characterized ultrahigh molecular weight sodium hyaluronate (NaHA) and blended pharmaceutical products containing NaHA using flow field-flow fractionation and multiangle light scattering-differential refractive index (FlFFF-MALS-DRI). NaHA is a water-soluble polysaccharide with a range of molecular weights (MW; 10 5~10 8 Da) that is found in body fluids and tissues. NaHA is also used commercially in pharmaceutical and cosmetic applications. We used a frit inlet asymmetrical FlFFF channel to separate aqueous polymers according to their hydrodynamic size, and we used on-line measurements of light scattering to obtain the MW distribution (MWD) as well as structural information about NaHA in aqueous solution. In this study, we investigated NaHA and anti-adhesive blend mixtures of NaHA (a commercial NaHA blend mixture containing sodium carboxymethyl cellulose and a new blend with hydroxyethyl starch (HES)) to determine the molecular weight distribution MWD of NaHA and the blend mixtures and to obtain structural information about these compounds in aqueous solution. We also examined the characteristics of NaHA-HES-polylactic-co-glycolic acid film products exposed to gamma radiation for sterilization purposes. © 2011 Springer-Verlag.


The present invention relates to a novel quinazoline-2,4-dione derivative of formula (I), a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising a compound of formula (I) as an active ingredient for preventing or treating neurological brain disease.


The present invention relates to a novel quinazoline-2,4-dione derivative of formula (I), a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising a compound of formula (I) as an active ingredient for preventing or treating neurological brain disease.


Trademark
Shin Poong Pharmaceutical Co. | Date: 2011-02-08

anti-malaria pharmaceutical preparations, agents for infectious diseases, namely, malaria, and pharmaceutical preparations for the treatment of infectious diseases, anti-infective combination pharmaceutical preparations for the treatment of malaria, pharmaceutical preparations, namely, anti-dermoinfectives for the treatment of malaria, Antiparasitic pharmaceutical preparations, Antipyretic preparations, Diaphoretics, Antibiotic preparations, Mixed antibiotic preparations.


Trademark
Shin Poong Pharmaceutical Co. | Date: 2010-12-17

Pharmaceutical preparations, namely, anti-malaria preparations, pharmaceuticals for treating infectious disease, anti-infective combination preparations, anti-parasitic preparations.


Trademark
Shin Poong Pharmaceutical Co. | Date: 2010-05-17

Anti-malaria pharmaceutical preparations, Agents for infectious diseases, namely, malaria, Pharmaceutical preparations for the treatment of infectious diseases, Anti-infective combination pharmaceutical preparations for the treatment of malaria, Pharmaceutical preparations, namely, anti-dermoinfectives, for the treatment of malaria, Anti-parasitic pharmaceutical preparations, Antipyretic preparations, Diaphoretics, Antibiotic preparations, Mixed antibiotic preparations.

Loading Shinpoong Pharmaceutical Co. collaborators
Loading Shinpoong Pharmaceutical Co. collaborators